Shanghai Wibson Biotechnology WBS Safety Rating & Test Results

As of 9 Aug 2026, Finnrick has published 48 independent lab tests of 6 peptides from Shanghai Wibson Biotechnology WBS: 38 passed, 9 failed, and 1 was not classifiable (incomplete data) under the default public standard, Purity Focus (HPLC purity at least 99.5%, fill within ±35% of the label claim). The latest test is dated 4 Aug 2026.

Finnrick ratings are recency-weighted pass percentages: newer tests count more, and vendors with thin test histories are pulled toward the peer baseline for that peptide, so a single result cannot look too certain. Samples are analyzed by independent partner laboratories and the results are published by Finnrick Analytics, which does not sell peptides and does not accept payment to alter ratings. Corrections to published data are recorded at finnrick.com/corrections.

Purchased from Shanghai Wibson Biotechnology WBS? Submit a sample to Finnrick for free independent lab testing — results are published publicly.

Are you Shanghai Wibson Biotechnology WBS? Finnrick offers professional testing services and a public launch program for peptide vendors.

Interactive charts, prices, and test history for this page load with JavaScript; the facts above are from Finnrick's published test database.

Shanghai Wibson Biotechnology WBS peptides tested by Finnrick, rated under the default public methodology.
PeptideFinnrick ratingLab testsLatest test
BPC-15759%523 Jul 2026
GHK-Cu86%423 Jul 2026
Ipamorelin71%44 Aug 2026
Retatrutide86%184 Aug 2026
Tesamorelin47%64 Aug 2026
Tirzepatide84%1120 Jul 2026